Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Grace Therapeutics, Inc.GRCE · Entity 7266 | Principal Financial Officer | August 28, 2026 | September 01, 2026 |
| ONCOSEC MEDICAL IncONCS · Entity 117092 | VP, Finance | February 09, 2023 | February 09, 2023 |
| U.S. GOLD CORP.USAU · Entity 6127 | See Remarks | April 10, 2018 | April 12, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Grace Therapeutics, Inc.
Report date August 28, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.12 · Expires 2036-08-27 | Direct | 33,660 |
Reported balance
After 2026-08-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-28 · Grant · Acquired 33,660 · Balance 33,660 F1: These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date.
ONCOSEC MEDICAL Inc
Report date February 09, 2023 · Filed February 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,008 |
Reported balance
After 2023-02-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-02-09 · Sale · Disposed 40 · Balance 1,008 F1: In connection with the vesting of 49 RSUs on February 1, 2023, a total of 40 shares were sold in order to satisfy the reporting person's tax withholding obligations. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies. F2: Effective as of 12:01 a.m. Eastern Time on November 9, 2022, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-22. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the vesting of 49 RSUs on February 1, 2023, a total of 40 shares were sold in order to satisfy the reporting person's tax withholding obligations. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies.
F2: Effective as of 12:01 a.m. Eastern Time on November 9, 2022, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-22.
U.S. GOLD CORP.
Report date April 10, 2018 · Filed April 12, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2023-04-10 | Direct | 0 |
Reported balance
After 2018-04-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-10 · Grant · Acquired 50,000 · Balance 0 F2: Option Award is compensation for the Reporting Person's service as Principal Financial and Accounting Officer of the Issuer. F1: Represents an option award (the "Option Award") under the U.S. Gold Corp. Equity Incentive Plan, which Option Award shall vest in equal quarterly installments beginning on the 90 day anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an option award (the "Option Award") under the U.S. Gold Corp. Equity Incentive Plan, which Option Award shall vest in equal quarterly installments beginning on the 90 day anniversary of the date of grant.
F2: Option Award is compensation for the Reporting Person's service as Principal Financial and Accounting Officer of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2026 Filed Sep 1, 2026 20:05 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 33,660 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001140361-26-035316 · form4.xml · derivative · entry 1 DelAversano Robert J · CIK 0001728262 · Principal Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,660 Underlying: Common Stock · 33,660 shares Expires 2036-08-27 F1 · derivative.exercise_date: These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date. Read SEC document |
| April 14, 2025 Filed Apr 17, 2025 00:58 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 20,130 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-25-014264 · form4.xml · derivative · entry 1 DelAversano Robert J · CIK 0001728262 · Principal Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,130 Underlying: Common Stock · 20,130 shares Expires 2035-04-14 F1 · derivative.exercise_date: This option vests quarterly in substantially equal installments over a 3-year period, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:18 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0000950170-24-056082 · ownership.xml · derivative · entry 1 DelAversano Robert J · CIK 0001728262 · Principal Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Class A Common Shares · 4,500 shares Expires 2034-05-06 F1 · derivative.exercise_date: Stock options granted on 05/06/2024 under the Acasti Pharma Stock Option Plan, which vest quarterly in equal installments over a 36-month period. Read SEC document |
| February 09, 2023 Filed Feb 9, 2023 20:11 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 40 | $1.37 | $54.80 |
DisclosureSEC source: 0001493152-23-004168 · ownership.xml · nonDerivative · entry 1 DelAversano Robert J · CIK 0001728262 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008 F1 · price: In connection with the vesting of 49 RSUs on February 1, 2023, a total of 40 shares were sold in order to satisfy the reporting person's tax withholding obligations. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies. F2 · balance_after: Effective as of 12:01 a.m. Eastern Time on November 9, 2022, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-22. Read SEC document |
| November 04, 2022 Filed Nov 4, 2022 20:21 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 283 | $0.37 | $104.71 |
DisclosureSEC source: 0001493152-22-030744 · ownership.xml · nonDerivative · entry 1 DelAversano Robert J · CIK 0001728262 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,975 F1 · price: In connection with the vesting of 1,093 RSUs on November 1, 2022, a total of 283 shares were sold in order to satisfy the reporting person's tax withholding obligations. This sale occurred automatically, and the amount sold corresponded to the tax withholding amount. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies. Read SEC document |
| August 05, 2022 Filed Aug 5, 2022 20:00 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 284 | $0.71 | $201.64 |
DisclosureSEC source: 0001493152-22-021536 · ownership.xml · nonDerivative · entry 1 DelAversano Robert J · CIK 0001728262 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,258 F1 · price: In connection with the vesting of 1,094 RSUs on August 1, 2022, a total of 284 shares were sold in order to satisfy the reporting person's tax withholding obligations. This sale occurred automatically, and the amount sold corresponded to the tax withholding amount. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies. Read SEC document |
| May 06, 2022 Filed May 6, 2022 12:35 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 274 | $0.83 | $227.42 |
DisclosureSEC source: 0001493152-22-012337 · ownership.xml · nonDerivative · entry 1 DelAversano Robert J · CIK 0001728262 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,542 F1 · price: In connection with the vesting of 1,094 RSUs on May 1, 2022, a total of 274 shares were sold on May 6, 2022, in order to satisfy the reporting person's tax withholding obligations. This sale occurred automatically, and the amount sold corresponded to the tax withholding amount. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 20:00 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 409 | $0.88 | $359.92 |
DisclosureSEC source: 0001493152-22-004150 · ownership.xml · nonDerivative · entry 1 DelAversano Robert J · CIK 0001728262 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,816 F1 · shares: In connection with the vesting of 1,094 RSUs on February 1, 2022, a total of 409 shares were sold in order to satisfy the reporting person's tax withholding obligations. This sale occurred automatically, and the amount sold corresponded to the tax withholding amount. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies. F1 · price: In connection with the vesting of 1,094 RSUs on February 1, 2022, a total of 409 shares were sold in order to satisfy the reporting person's tax withholding obligations. This sale occurred automatically, and the amount sold corresponded to the tax withholding amount. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:00 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 343 | $1.75 | $600.25 |
DisclosureSEC source: 0001493152-21-027164 · ownership.xml · nonDerivative · entry 1 DelAversano Robert J · CIK 0001728262 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,225 F1 · shares: In connection with the vesting of 1,093 RSUs on November 1, 2021, a total of 343 shares were sold in order to satisfy the reporting person's tax withholding obligations. This sale occurred automatically, and the amount sold corresponded to the tax withholding amount. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies. F1 · price: In connection with the vesting of 1,093 RSUs on November 1, 2021, a total of 343 shares were sold in order to satisfy the reporting person's tax withholding obligations. This sale occurred automatically, and the amount sold corresponded to the tax withholding amount. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 20:14 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 412 | $2.18 | $898.16 |
DisclosureSEC source: 0001493152-21-018477 · ownership.xml · nonDerivative · entry 1 DelAversano Robert J · CIK 0001728262 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,568 F1 · shares: In connection with the vesting of 1,094 RSUs on August 1, 2021, a total of 412 shares were sold in order to satisfy the reporting person's tax withholding obligations. This sale occurred automatically, and the amount sold corresponded to the tax withholding amount. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies. F1 · price: In connection with the vesting of 1,094 RSUs on August 1, 2021, a total of 412 shares were sold in order to satisfy the reporting person's tax withholding obligations. This sale occurred automatically, and the amount sold corresponded to the tax withholding amount. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 19:43 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001493152-21-015622 · ownership.xml · derivative · entry 1 DelAversano Robert J · CIK 0001728262 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-06-28 F1 · derivative.exercise_date: The option was 25% vested upon grant, and the remainder will vest in equal quarterly installments over the next two years. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:00 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 453 | $4.86 | $2,201.58 |
DisclosureSEC source: 0001493152-21-010453 · ownership.xml · nonDerivative · entry 1 DelAversano Robert J · CIK 0001728262 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,980 F1 · shares: In connection with the vesting of 1,094 RSUs on May 1, 2021, a total of 453 shares were sold in order to satisfy the reporting person's tax withholding obligations. This sale occurred automatically, and the amount sold corresponded to the tax withholding amount. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies. F1 · price: In connection with the vesting of 1,094 RSUs on May 1, 2021, a total of 453 shares were sold in order to satisfy the reporting person's tax withholding obligations. This sale occurred automatically, and the amount sold corresponded to the tax withholding amount. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:42 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-002566 · ownership.xml · nonDerivative · entry 1 DelAversano Robert J · CIK 0001728262 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,433 F1 · shares: This is a long-term equity incentive award of restricted stock units which will vest quarterly over the next two years. The first vesting will occur on 5/1/2021, and the award will be fully vested on 2/1/2023, pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan. F1 · price: This is a long-term equity incentive award of restricted stock units which will vest quarterly over the next two years. The first vesting will occur on 5/1/2021, and the award will be fully vested on 2/1/2023, pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 20:00 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001493152-20-016792 · ownership.xml · derivative · entry 1 DelAversano Robert J · CIK 0001728262 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2030-08-24 F1 · derivative.exercise_date: The option vests quarterly over the next three years. Read SEC document |
| May 29, 2020 Filed Jun 3, 2020 21:16 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 54,054 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001493152-20-010512 · ownership.xml · derivative · entry 3 DelAversano Robert J · CIK 0001728262 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,054 Underlying: Common Stock · 54,054 shares Expires 2030-04-14 F1 · date: The option grant was approved by the Issuer's Compensation Committee on April 14, 2020, subject to stockholder approval of an amendment to the Issuer's 2011 Incentive Plan to increase the number of authorized shares. The Issuer's stockholders approved the plan amendment on May 29, 2020. F2 · derivative.exercise_date: The option was 25% vested on April 14, 2020, and the remainder vests quarterly over the next three years. Read SEC document |
| May 29, 2020 Filed Jun 3, 2020 21:16 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Tax withholdingCommon Stock | 8,679 | $2.23 | $19,354.17 |
DisclosureSEC source: 0001493152-20-010512 · ownership.xml · nonDerivative · entry 2 DelAversano Robert J · CIK 0001728262 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,683 Read SEC document |
| May 29, 2020 Filed Jun 3, 2020 21:16 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantCommon Stock | 25,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-010512 · ownership.xml · nonDerivative · entry 1 DelAversano Robert J · CIK 0001728262 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,362 Read SEC document |
| April 10, 2018 Filed Apr 12, 2018 20:05 UTC | U.S. GOLD CORP. USAU · Entity 6127 | GrantOption · Derivative | 50,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001493152-18-005083 · form-4.xml · derivative · entry 1 DelAversano Robert J · CIK 0001728262 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2023-04-10 F2 · price: Option Award is compensation for the Reporting Person's service as Principal Financial and Accounting Officer of the Issuer. F1 · derivative.exercise_date: Represents an option award (the "Option Award") under the U.S. Gold Corp. Equity Incentive Plan, which Option Award shall vest in equal quarterly installments beginning on the 90 day anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.